BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10478180)

  • 1. [Clinical effect of idarubicin on malignant lymphoma].
    Urabe A; Ohno R; Kuraishi Y; Masaoka T; Ohashi Y; Ogawa M
    Gan To Kagaku Ryoho; 1999 Aug; 26(9):1275-82. PubMed ID: 10478180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Late phase II clinical study of amrubicin hydrochloride, a novel synthetic anthracycline derivative anticancer agent, for malignant lymphoma].
    Akutsu M; Kano Y; Ogawa M; Miura A; Hirano M; Masaoka T; Tatsumi N
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1867-76. PubMed ID: 11729479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Menogaril (TUT-7) late phase II study for malignant lymphoma, adult T-cell leukemia and lymphoma (ATLL)].
    Taguchi T; Ohta K; Hotta T; Shirakawa S; Masaoka T; Kimura I
    Gan To Kagaku Ryoho; 1997 Aug; 24(10):1263-71. PubMed ID: 9279345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Early phase II clinical trial of amrubicin hydrochloride in patients with malignant lymphoma].
    Masaoka T; Ogawa M; Inoue K; Sanpi K; Kuraishi Y; Toki H; Tamura K; Takagi T; Shibata A; Hirano M; Ezaki K; Shirakawa S; Matsuda T; Kimura I
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1857-65. PubMed ID: 11729478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Phase II study of KRN8602 (MX2) for malignant lymphoma].
    Okabe K; Sampi K; Kuraishi Y; Takemoto Y; Tamura K; Ogawa M
    Gan To Kagaku Ryoho; 1998 Jun; 25(7):1001-6. PubMed ID: 9644314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
    Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
    Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Early phase II study of Idarubicin, a new anthracycline anticancer drug, in acute leukemia. Idarubicin Study Group].
    Ogawa M; Masaoka T; Yamada K; Kimura K
    Gan To Kagaku Ryoho; 1993 May; 20(7):897-906. PubMed ID: 8489296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia.
    Karbasian-Esfahani M; Wiernik PH; Novik Y; Paietta E; Dutcher JP
    Cancer; 2004 Sep; 101(6):1414-9. PubMed ID: 15368329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of oral idarubicin in favorable histology non-Hodgkin's lymphoma.
    Case DC; Hayes DM; Gerber M; Gams R; Ervin TJ; Dorsk BM
    Cancer Res; 1990 Nov; 50(21):6833-5. PubMed ID: 2208149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma.
    Case DC; Gerber MC; Gams RA; Crawford J; Votaw ML; Higano CS; Pruitt BT; Gould J
    Cancer Res; 1992 Jul; 52(14):3871-4. PubMed ID: 1617662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Late phase II study with 21-consecutive-day oral administration of etoposide for malignant lymphoma].
    Yoshida T; Takagi T; Shimoyama M; Mikuni C; Suzuki K; Egami K; Furusawa S; Nomura T; Mori M; Sugimoto T
    Gan To Kagaku Ryoho; 1994 Dec; 21(16):2793-801. PubMed ID: 7993116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of infusional cyclophosphamide, idarubicin, and etoposide in poor prognosis non-Hodgkin's lymphoma.
    Salman H; Perez A; Sparano JA; Ratech H; Negassa A; Hopkins U; Villani G; Fuks J; Wiernik PH
    Am J Clin Oncol; 2003 Aug; 26(4):338-43. PubMed ID: 12902881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A late phase II study of idarubicin hydrochloride in adult patients with acute lymphocytic leukemia. Idarubicin Study Group].
    Masaoka T; Ogawa M; Yamada K; Kimura K
    Gan To Kagaku Ryoho; 1993 Oct; 20(13):2007-14. PubMed ID: 8215475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
    Borghaei H; Millenson M; Schilder R; Alden M; Rogatko A; Wang H; Padavic-Shaller K; Smith MR
    Cancer; 2004 Nov; 101(9):2034-41. PubMed ID: 15455357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Late phase II study of MST-16 (sobuzoxane) efficacy for malignant lymphoma].
    Masaoka T; Kageyama T; Tatsumi N; Akasaka K; Yonezawa T; Sugiyama H; Kitani T; Yasunaga K; Horiuchi A; Nakayama S
    Gan To Kagaku Ryoho; 1992 Mar; 19(3):339-47. PubMed ID: 1543360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
    Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Phase II study of etoposide (VP-16) in the form of intravenous injection for malignant lymphomas and acute leukemias: Hanshin Cooperative Study Group for Hematological Disorders].
    Tagawa S; Kitani T; Nagai K; Kanamaru A; Kohsaki M; Masaoka T; Shibata H; Horiuchi A; Tsubaki K; Kawagoe H
    Gan No Rinsho; 1987 Jan; 33(1):1-7. PubMed ID: 3469424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A phase I trial of idarubicin by oral administration].
    Ogawa M; Kimura K; Taguchi T; Wakui A; Hattori M; Shimoyama T; Fujita H
    Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1896-900. PubMed ID: 3473981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia.
    Weiss MA; Aliff TB; Tallman MS; Frankel SR; Kalaycio ME; Maslak PG; Jurcic JG; Scheinberg DA; Roma TE
    Cancer; 2002 Aug; 95(3):581-7. PubMed ID: 12209751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.